Provention Bio’s Teplizumab Delays Type 1 Diabetes Onset, US FDA Says

 
• By Sue Sutter
Alarm clock delay
In the pivotal trial, teplizumab delayed the diagnosis of type 1 diabetes by 2 years. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers